Table 3 Correlation of epicardial fat with markers for body composition and cardio-metabolic risks in patients with type 2 diabetes
From: Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study
| Â | r | p values |
|---|---|---|
Body composition markers | ||
 Body weight (kg) | 0.310 | 0.196 |
 Body mass index (kg/m2) | 0.485 | 0.044 |
 Waist circumference (cm) | 0.364 | 0.126 |
 Visceral fat area (cm2) | 0.467 | 0.044 |
 Subcutaneous fat area (cm2) | 0.452 | 0.052 |
 Liver attenuation index | −0.210 | 0.388 |
 Body fat (%) | 0.249 | 0.304 |
 Total fat mass (kg) | 0.484 | 0.036 |
 Total non-fat mass (kg) | 0.103 | 0.675 |
 Skeletal muscle index | 0.233 | 0.337 |
Cardio-metabolic markers | ||
 HbA1c (%) | −0.312 | 0.193 |
 HOMA-IR | 0.502 | 0.046 |
 Triglycerides (mmol/l) | −0.100 | 0.684 |
 HDL cholesterol (mmol/l) | −0.041 | 0.869 |
 SBP (mmHg) | 0.073 | 0.765 |
 DBP (mmHg) | 0.309 | 0.198 |
 ALT (U/l) | 0.175 | 0.475 |
 Log CRP (mg/l) | 0.130 | 0.608 |
 Log ACR (mg/g) | −0.143 | 0.561 |
 Adiponectin (μg/ml) | 0.159 | 0.608 |
 Leptin (ng/ml) | −0.143 | 0.561 |
 Log interleukin 6 (pg/ml) | 0.174 | 0.490 |